1 nnels, a very prolonged recovery from anoxic stupor, a vulnerability to heat shock and increased O2 d

2  2 had transient ischemic attacks, and 1 had stupor), and 3.0 percent had type II outcomes (55 had de

3    Reference standard diagnoses of delirium, stupor, and coma occurred in 25.2%, 21.3%, and 28.5% of

4 d pressure, abnormal pupillary reflexes, and stupor/coma.

5                     Reversible somnolence or stupor occurred in 3 patients at arginine butyrate doses

6 neurologic outcome: type I (focal injury, or stupor or coma at discharge) and type II (deterioration

7 athy with motor regression, irritability and stupor or coma resulting in major handicap or death.

8 s, resulting in their premature arousal from stupor with catastrophic consequences.